Chris Beddardeditorial@labpulse.comInfectiousThe next phase of diagnostic testing is here and ready to scaleIt is time to provide more advanced insight on patient health and more informed treatment options for clinicians in the U.S. Few diagnostic tools and systems on the market today are available to scale and even fewer provide extended genotyping capabilities. This gap can hamper patient care by masking or misdiagnosing illnesses and strains, potentially leading physicians to advise treatment plans that lack precision or that may be unnecessary.November 10, 2021Page 1 of 1Top StoriesCancerInvivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detectionUnder the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics' NGS platforms.Regulatory ApprovalSeegene obtains IVDR certification for 30 diagnostic assaysPolicy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsCollaborationNucleai, Adlai Nortye collaborate on biomarkers for clinical trialsSponsor ContentVisit our Molecular Diagnostics Community